Levorphanol #240

Loitman, Jane E.

doi:10.1089/jpm.2011.9673

Search citation statements

Order By: Relevance

Paper Sections

Select...

Levorphanol: Pharmacologic Characteristics1

Levorphanol (Po)1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

2020

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 18 There is no cytochrome P450 system involvement in this process, limiting drug–drug interaction. 19 …”

Section: Levorphanol: Pharmacologic Characteristicsmentioning

confidence: 99%

<p>Levorphanol in the Perioperative Setting: Decreasing Opioid Requirements While Improving Pain Management</p>

Page

Perez

Mavarez-Martinez

et al. 2020

JPR

View full text Add to dashboard Cite

“… 18 There is no cytochrome P450 system involvement in this process, limiting drug–drug interaction. 19 …”

Section: Levorphanol: Pharmacologic Characteristicsmentioning

confidence: 99%

<p>Levorphanol in the Perioperative Setting: Decreasing Opioid Requirements While Improving Pain Management</p>

Page

Perez

Mavarez-Martinez

et al. 2020

JPR

View full text Add to dashboard Cite

“…Its long halflife (11-16 hours) means baseline doses should not be increased before steady state is reached (2-3 days). Table 3 shows the equianalgesic ratio of levorphanol (and methadone) to morphine varies by dose (Loitman, 2011). Phase 2 metabolism results in inactive metabolites excreted in urine.…”

Section: Levorphanol (Po)mentioning

confidence: 99%

Cancer Pain Management: Opioid Analgesics, Part 2

Wickham

2017

JADPRO

View full text Add to dashboard Cite

Opioid analgesics are the cornerstone of moderate to severe cancer pain management, and do not have ceiling doses unless unmanageable adverse effects occur. Oral, short-acting pure μ agonists such as morphine are most frequently used, but other agents and administration formulations allow finding the right opioid and dose for most patients. In addition, clinicians must understand the metabolism, pharmacokinetics, and elimination of particular drugs to individualize opioid selection, select initial doses, and appropriately escalate doses to satisfactory pain relief or uncontrollable toxicity. Anticipation and proactive management of possible adverse effects, particularly constipation, confusion or delirium, opioid-specific adverse effects, and opioid abuse, are also integral to primary and secondary prophylaxis and management.

show abstract

Levorphanol #240

Cited by 2 publications

References 5 publications

<p>Levorphanol in the Perioperative Setting: Decreasing Opioid Requirements While Improving Pain Management</p>

<p>Levorphanol in the Perioperative Setting: Decreasing Opioid Requirements While Improving Pain Management</p>

Cancer Pain Management: Opioid Analgesics, Part 2

Contact Info

Product

Resources

About